560 related articles for article (PubMed ID: 36270731)
1. Combining precision oncology and immunotherapy by targeting the MALT1 protease.
Mempel TR; Krappmann D
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36270731
[TBL] [Abstract][Full Text] [Related]
2. Function and targeting of MALT1 paracaspase in cancer.
O'Neill TJ; Tofaute MJ; Krappmann D
Cancer Treat Rev; 2023 Jun; 117():102568. PubMed ID: 37126937
[TBL] [Abstract][Full Text] [Related]
3. MALT1 Proteolytic Activity Suppresses Autoimmunity in a T Cell Intrinsic Manner.
Demeyer A; Skordos I; Driege Y; Kreike M; Hochepied T; Baens M; Staal J; Beyaert R
Front Immunol; 2019; 10():1898. PubMed ID: 31474984
[TBL] [Abstract][Full Text] [Related]
4. A patent review of MALT1 inhibitors (2013-present).
Hamp I; O'Neill TJ; Plettenburg O; Krappmann D
Expert Opin Ther Pat; 2021 Dec; 31(12):1079-1096. PubMed ID: 34214002
[TBL] [Abstract][Full Text] [Related]
5. Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy.
Liu X; Si F; Bagley D; Ma F; Zhang Y; Tao Y; Shaw E; Peng G
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36192086
[TBL] [Abstract][Full Text] [Related]
6. Malt1 self-cleavage is critical for regulatory T cell homeostasis and anti-tumor immunity in mice.
Baens M; Stirparo R; Lampi Y; Verbeke D; Vandepoel R; Cools J; Marynen P; de Bock CE; Bornschein S
Eur J Immunol; 2018 Oct; 48(10):1728-1738. PubMed ID: 30025160
[TBL] [Abstract][Full Text] [Related]
7. Bcl10-controlled Malt1 paracaspase activity is key for the immune suppressive function of regulatory T cells.
Rosenbaum M; Gewies A; Pechloff K; Heuser C; Engleitner T; Gehring T; Hartjes L; Krebs S; Krappmann D; Kriegsmann M; Weichert W; Rad R; Kurts C; Ruland J
Nat Commun; 2019 May; 10(1):2352. PubMed ID: 31138793
[TBL] [Abstract][Full Text] [Related]
8. Expression of costimulatory and inhibitory receptors in FoxP3
Toker A; Ohashi PS
Adv Cancer Res; 2019; 144():193-261. PubMed ID: 31349899
[TBL] [Abstract][Full Text] [Related]
9. TRAF6 controls T cell homeostasis by maintaining the equilibrium of MALT1 scaffolding and protease functions.
O'Neill TJ; Gewies A; Seeholzer T; Krappmann D
Front Immunol; 2023; 14():1111398. PubMed ID: 36761777
[TBL] [Abstract][Full Text] [Related]
10. Targeting MALT1 for the treatment of diffuse large B-cell lymphoma.
Seshadri MR; Melnick AM
Leuk Lymphoma; 2022 Apr; 63(4):789-798. PubMed ID: 34783281
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Potential of Targeting Malt1-Dependent TCR Downstream Signaling to Promote the Survival of MHC-Mismatched Allografts.
Govender L; Mikulic J; Wyss JC; Gaide O; Thome M; Golshayan D
Front Immunol; 2020; 11():576651. PubMed ID: 33042160
[TBL] [Abstract][Full Text] [Related]
12. MALT1 Phosphorylation Controls Activation of T Lymphocytes and Survival of ABC-DLBCL Tumor Cells.
Gehring T; Erdmann T; Rahm M; Graß C; Flatley A; O'Neill TJ; Woods S; Meininger I; Karayel O; Kutzner K; Grau M; Shinohara H; Lammens K; Feederle R; Hauck SM; Lenz G; Krappmann D
Cell Rep; 2019 Oct; 29(4):873-888.e10. PubMed ID: 31644910
[TBL] [Abstract][Full Text] [Related]
13. Targeting the CBM complex causes T
Di Pilato M; Kim EY; Cadilha BL; Prüßmann JN; Nasrallah MN; Seruggia D; Usmani SM; Misale S; Zappulli V; Carrizosa E; Mani V; Ligorio M; Warner RD; Medoff BD; Marangoni F; Villani AC; Mempel TR
Nature; 2019 Jun; 570(7759):112-116. PubMed ID: 31092922
[TBL] [Abstract][Full Text] [Related]
14. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
15. A MALT1 inhibitor suppresses human myeloid DC, effector T-cell and B-cell responses and retains Th1/regulatory T-cell homeostasis.
Dumont C; Sivars U; Andreasson T; Odqvist L; Mattsson J; DeMicco A; Pardali K; Johansson G; Yrlid L; Cox RJ; Seeliger F; Larsson M; Gehrmann U; Davis AM; Vaarala O
PLoS One; 2020; 15(9):e0222548. PubMed ID: 32870913
[TBL] [Abstract][Full Text] [Related]
16. Malt1 Protease Is Critical in Maintaining Function of Regulatory T Cells and May Be a Therapeutic Target for Antitumor Immunity.
Cheng L; Deng N; Yang N; Zhao X; Lin X
J Immunol; 2019 May; 202(10):3008-3019. PubMed ID: 30979818
[TBL] [Abstract][Full Text] [Related]
17. Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer.
Revenko A; Carnevalli LS; Sinclair C; Johnson B; Peter A; Taylor M; Hettrick L; Chapman M; Klein S; Solanki A; Gattis D; Watt A; Hughes AM; Magiera L; Kar G; Ireland L; Mele DA; Sah V; Singh M; Walton J; Mairesse M; King M; Edbrooke M; Lyne P; Barry ST; Fawell S; Goldberg FW; MacLeod AR
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35387780
[TBL] [Abstract][Full Text] [Related]
18. MALT1 protease: a new therapeutic target in B lymphoma and beyond?
McAllister-Lucas LM; Baens M; Lucas PC
Clin Cancer Res; 2011 Nov; 17(21):6623-31. PubMed ID: 21868762
[TBL] [Abstract][Full Text] [Related]
19. Remodeling of the tumor microenvironment via disrupting Blimp1
Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
[TBL] [Abstract][Full Text] [Related]
20. Targeting the immune microenvironment for ovarian cancer therapy.
Blanc-Durand F; Clemence Wei Xian L; Tan DSP
Front Immunol; 2023; 14():1328651. PubMed ID: 38164130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
